DK0889880T3 - Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering - Google Patents

Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering

Info

Publication number
DK0889880T3
DK0889880T3 DK97917004T DK97917004T DK0889880T3 DK 0889880 T3 DK0889880 T3 DK 0889880T3 DK 97917004 T DK97917004 T DK 97917004T DK 97917004 T DK97917004 T DK 97917004T DK 0889880 T3 DK0889880 T3 DK 0889880T3
Authority
DK
Denmark
Prior art keywords
formulation
preparation
eprosartan
dihydrate
eprosartan dihydrate
Prior art date
Application number
DK97917004T
Other languages
Danish (da)
English (en)
Inventor
Nageswara R Palepu
Gopadi M Venkatesh
Sarma Duddu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0889880(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0889880T3 publication Critical patent/DK0889880T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK97917004T 1996-03-29 1997-03-26 Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering DK0889880T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (1)

Publication Number Publication Date
DK0889880T3 true DK0889880T3 (da) 2003-09-01

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97917004T DK0889880T3 (da) 1996-03-29 1997-03-26 Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering

Country Status (36)

Country Link
EP (1) EP0889880B1 (pt)
JP (1) JP4316013B2 (pt)
CN (2) CN1214682A (pt)
AP (1) AP901A (pt)
AR (1) AR006439A1 (pt)
AT (1) ATE239723T1 (pt)
AU (1) AU726694B2 (pt)
BG (1) BG64095B1 (pt)
BR (1) BR9708336A (pt)
CA (1) CA2250395C (pt)
CZ (1) CZ293345B6 (pt)
DE (1) DE69721749T2 (pt)
DK (1) DK0889880T3 (pt)
DZ (1) DZ2199A1 (pt)
EA (1) EA001958B1 (pt)
EG (1) EG23889A (pt)
ES (1) ES2198564T3 (pt)
HK (1) HK1016594A1 (pt)
HU (1) HU228263B1 (pt)
ID (1) ID16507A (pt)
IL (1) IL126319A0 (pt)
MA (1) MA24437A1 (pt)
MY (1) MY117682A (pt)
NO (2) NO311760B1 (pt)
NZ (1) NZ332008A (pt)
OA (1) OA11176A (pt)
PL (1) PL188816B1 (pt)
PT (1) PT889880E (pt)
RO (1) RO118870B1 (pt)
SK (1) SK282346B6 (pt)
TR (1) TR199801954T2 (pt)
TW (1) TW434239B (pt)
UA (1) UA49880C2 (pt)
UY (1) UY24504A1 (pt)
WO (1) WO1997036874A1 (pt)
ZA (1) ZA972686B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69807695T2 (de) * 1997-06-27 2003-07-31 Smithkline Beecham Corp Eprosartan-monohydrate
KR100597922B1 (ko) * 1997-11-17 2006-07-10 스미스클라인 비참 코포레이션 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
BR9908474A (pt) 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
HUP0103000A3 (en) * 1998-07-20 2002-08-28 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form and process for their preparation
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
WO2000027396A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
PT1197223E (pt) * 1999-04-28 2005-04-29 Takeda Pharmaceutical Preventivos/medicamentos/inibidores da progressao de retinopatia simples ou retinopatia pre-proliferativa
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
CN1651087A (zh) * 2000-04-12 2005-08-10 诺瓦提斯公司 有机化合物的联合形式
PL370270A1 (en) * 2001-11-23 2005-05-16 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AU2003240670A1 (en) * 2002-05-17 2003-12-02 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
NZ541454A (en) 2003-01-31 2008-04-30 Daiichi Sankyo Co Ltd Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2009013760A2 (en) 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0563238B1 (en) * 1990-12-14 2002-05-22 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
ZA972686B (en) 1997-09-29
CN1332167A (zh) 2002-01-23
NO984503D0 (no) 1998-09-28
MY117682A (en) 2004-07-31
HU228263B1 (en) 2013-02-28
UY24504A1 (es) 1997-09-19
ES2198564T3 (es) 2004-02-01
TW434239B (en) 2001-05-16
WO1997036874A1 (en) 1997-10-09
JP2000508632A (ja) 2000-07-11
CN1214682A (zh) 1999-04-21
NO2002005I1 (no) 2002-09-02
AP9700956A0 (en) 1997-04-30
DE69721749D1 (de) 2003-06-12
HUP9902769A2 (hu) 2000-03-28
RO118870B1 (ro) 2003-12-30
EP0889880B1 (en) 2003-05-07
TR199801954T2 (xx) 1998-12-21
NO311760B1 (no) 2002-01-21
ID16507A (id) 1997-10-02
SK132298A3 (en) 1999-03-12
AP901A (en) 2000-11-23
PL188816B1 (pl) 2005-04-29
JP4316013B2 (ja) 2009-08-19
EA199800873A1 (ru) 1999-02-25
BG64095B1 (bg) 2003-12-31
BR9708336A (pt) 1999-08-03
DE69721749T2 (de) 2004-03-25
CA2250395C (en) 2005-09-06
OA11176A (en) 2003-05-13
ATE239723T1 (de) 2003-05-15
CZ293345B6 (cs) 2004-04-14
HUP9902769A3 (en) 2000-04-28
NO984503L (no) 1998-09-28
EP0889880A1 (en) 1999-01-13
CA2250395A1 (en) 1997-10-09
HK1016594A1 (en) 1999-11-05
IL126319A0 (en) 1999-05-09
PT889880E (pt) 2003-09-30
DZ2199A1 (fr) 2002-12-03
CZ310198A3 (cs) 1999-03-17
EG23889A (en) 2007-12-12
EA001958B1 (ru) 2001-10-22
SK282346B6 (sk) 2002-01-07
NZ332008A (en) 1999-05-28
PL329046A1 (en) 1999-03-01
AU726694B2 (en) 2000-11-16
MA24437A1 (fr) 1998-10-01
AR006439A1 (es) 1999-08-25
BG102822A (en) 1999-11-30
EP0889880A4 (en) 1999-06-23
AU2547097A (en) 1997-10-22
UA49880C2 (uk) 2002-10-15

Similar Documents

Publication Publication Date Title
DK0889880T3 (da) Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
DK0850948T3 (da) Propiophenonderivater og fremgangsmåde til fremstilling deraf
DE69634256D1 (de) Zementformulierung
DK0739898T3 (da) Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf
NO974528L (no) Sementeringsslurry og fremgangsmåte til utforming av formulering
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
DK0985697T3 (da) Oxiranderivater og fremgangsmåde til fremstilling deraf
EE9900014A (et) Erütromütsiinid ja nende valmistamise protsess
DK0799052T3 (da) Ny antihrombotisk formulering, fremgangsmåde til dens fremstilling og anvendelse deraf
DK0926952T3 (da) Antimikrobiel sammensætning og fremgangsmåde til fremstilling deraf
DK1015444T3 (da) Pyrimidinderivater og fremgangsmåder til fremstilling deraf
ID22755A (id) Proses prapengolahan kosmetik bekas
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
DK0977812T3 (da) Asfaltsammensætninger og fremgangsmåder til fremstilling deraf
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20002202D0 (no) Støpte polyolefin- og polyfenyloksidprodukter og fremgangsmÕte til fremstilling derav
NO985385L (no) Bitumensammensetninger og fremgangsmÕte for fremstilling derav
DK1003383T4 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK0735042T3 (da) Maltitolsammensætning og fremgangsmåde til fremstilling deraf
ID18793A (id) Bahan penahan untuk pestisida
DK0791591T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder til deres fremstilling
DE69942195D1 (de) Prozesssystem und -verfahren
NO991749D0 (no) Sammensetninger til bruk i betong og betongprodukter fremstilt derav
NO981784L (no) Fremgangsmaate til tilberedning av sementblandinger og blander til bruk for utförelse av fremgangsmaaten